- Home
- CHNR vs SILO Comparison
CHNR vs SILO Comparison
Compare CHNR & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | SILO |
|---|---|---|
| Founded | N/A | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Apparel |
| Sector | Basic Materials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.5M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHNR | SILO |
|---|---|---|
| Price | $3.42 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.7K | ★ 103.7K |
| Earning Date | 12-31-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $0.27 |
| 52 Week High | $8.20 | $1.57 |
Technical Indicators
Market Signals| Indicator | CHNR | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 35.36 |
| Support Level | $3.50 | $0.29 |
| Resistance Level | $3.83 | $0.33 |
| Average True Range (ATR) | 0.31 | 0.03 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 0.00 | 19.14 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.